{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:14:23Z","timestamp":1773418463505,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi\u2010Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Atrial fibrillation (<jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>) is associated with high morbidity and mortality, even despite the use of oral anticoagulation (<jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>). Soluble suppression of tumorigenicity\u20102 (<jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2) is a member of the interleukin\u20101 receptor family [interleukin\u20101 receptor\u2010like 1 (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content>1)], which has been associated with an increased risk of mortality and morbidity in heart failure or acute coronary syndrome. We assessed the predictive value of <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 levels in an unselected \u2018real\u2010world\u2019 cohort of anticoagulated <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 562 patients (49% male; median age 77 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>: 71\u201382]) with permanent <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> who were stable (for at least 6\u00a0months) on <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">INR<\/jats:styled-content>s 2\u00b70\u20133\u00b70). <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 levels were quantified by <jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content>. Patients were followed\u2010up for up to 4\u00a0years, and cardiovascular events and all\u2010cause mortality were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>) of <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 levels was 51\u00b723 (39\u00b709\u201367\u00b740)\u00a0\u03bcg\/L. Median follow\u2010up was 1587\u00a0days [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 1482\u20131617], and during this period, 91 patients died (16\u00b72%, 3\u00b772%\/year). The c\u2010statistic for predicting mortality with <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 was 0\u00b758\u00a0+\u00a00\u00b703; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7017). On multivariate analysis, age [hazard ratio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) 1\u00b709 (1\u00b705\u20131\u00b713); <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001], diabetes mellitus [1\u00b776 (1\u00b708\u20132\u00b788); <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7023], previous stroke [2\u00b716 (1\u00b729\u20133\u00b760); <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7003] and <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 levels [1\u00b7008 (1\u00b7002\u20131\u00b714); <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7008] were independently associated with mortality. Concentrations of <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 were also significantly associated with the risk of mortality, even after adjusting for the <jats:styled-content style=\"fixed-case\">CHA<\/jats:styled-content><jats:sub>2<\/jats:sub><jats:styled-content style=\"fixed-case\">DS<\/jats:styled-content><jats:sub>2<\/jats:sub>\u2013<jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>c score [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>: 1\u00b7007 (1\u00b7001\u20131\u00b7013); <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7014].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In an anticoagulated <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> patient's cohort, <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 levels are an independent predictive factor of all\u2010cause mortality. <jats:styled-content style=\"fixed-case\">sST<\/jats:styled-content>2 levels could be a biomarker used to improve clinical risk assessment in anticoagulated <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.12482","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T07:37:30Z","timestamp":1434526650000},"page":"899-905","source":"Crossref","is-referenced-by-count":21,"title":["sST2 levels are associated with all\u2010cause mortality in anticoagulated patients with atrial fibrillation"],"prefix":"10.1111","volume":"45","author":[{"given":"Juan A.","family":"V\u00edlchez","sequence":"first","affiliation":[{"name":"Departments of Cardiology and Clinical Analysis Clinic University Hospital Virgen de la Arrixaca IMIB\u2010Arrixaca Murcia Spain"},{"name":"Department of Biochemistry and Molecular Biology Universitat Aut\u00f2noma Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"P\u00e9rez\u2010Cuellar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology Universitat Aut\u00f2noma Barcelona Spain"},{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"IIB\u2010Sant Pau Biomedical Research Institute Hospital Santa Creu i Sant Pau Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"Department of Cardiology of Clinic University Hospital Virgen de la Arrixaca IMIB\u2010Arrixaca Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Gallego","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Unit General University Hospital Morales Meseguer Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Manzano\u2010Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"Department of Cardiology of Clinic University Hospital Virgen de la Arrixaca IMIB\u2010Arrixaca Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Vald\u00e9s","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"Department of Cardiology of Clinic University Hospital Virgen de la Arrixaca IMIB\u2010Arrixaca Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Vicente","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"Hematology and Medical Oncology Unit General University Hospital Morales Meseguer Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Noguera\u2010Velasco","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology Universitat Aut\u00f2noma Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis Clinic University Hospital Virgen de la Arrixaca IMIB\u2010Arrixaca Murcia Spain"},{"name":"Centre for Cardiovascular Sciences University of Birmingham City Hospital Birmingham UK"},{"name":"Aalborg Thrombosis Research Unit Department of Clinical Medicine Aalborg University Aalborg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ord\u00f3\u00f1ez\u2010Llanos","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology Universitat Aut\u00f2noma Barcelona Spain"},{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"IIB\u2010Sant Pau Biomedical Research Institute Hospital Santa Creu i Sant Pau Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n Cardiovascular Instituto de Salud Carlos III Madrid Spain"},{"name":"Hematology and Medical Oncology Unit General University Hospital Morales Meseguer Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267275.68538.8d"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.04.016"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2012.02.017"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12304"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000038705.69871.D9"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03441.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-010-0005-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000047274.66749.FE"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.096560"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.05.014"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.080382"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000065232.57371.25"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2010.10.008"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02373-2"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000046452.67724.B8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30634"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127958.21003.5A"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.833707"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.728022"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.672402"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.129437"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2008.06.415"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2008.03.002"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.003338"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0922"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-198"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28481"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Feci.12482","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.12482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:52:29Z","timestamp":1695574349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.12482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/eci.12482"],"URL":"https:\/\/doi.org\/10.1111\/eci.12482","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}